IMMP

Immutep Ltd. ADR (IMMP) | Rumor.io

Immutep

IMMP

Attention (50-day avg)0%

Attention rank (50-day avg)#1,806

Bullish sentiment (50-day avg)77%

Price to earnings ratio-8.98

Market capitalization713.3M

Earnings per share-0.38

Dividend yield (TTM)—

Revenue (annual)14.6M

Net income (annual)-79.3M

Social

What share of all stock conversation is about IMMP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% -0.02	0% +0	0% +0	0% 0

Sep 28

Immutep's efti LAG-3 immunotherapy trial delivers explosive clinical data, with the company's stock experiencing a significant surge in value.
The stock's price has created a chart gap, with volume reaching monster levels.
Technical analysts see potential for the stock to break above resistance at $0.43-$0.50.

Generated by AI

Sentiment

Of the messages about IMMP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% -100	78.57% +11.9	82.54% -0.18
Bearish	—	100% new	21.43% -11.9	17.46% +0.18

Bullish· Apr 16

Immutep Limited's ($IMMP) FDA Orphan Drug Designation for efti has driven a significant price increase, with the stock potentially running toward $1.20.
The company's Phase II data and FDA momentum have caused a "burn notice" for short sellers, with the stock's volume supporting a potential run toward $1.20.
$IMMP has the potential to reach $1 or higher, with some traders predicting a 50-70% increase in value following the FDA news.

Bearish· Apr 16

$IMMP is likely to break below $1.00 and revisit $0.50.
Traders are expecting a selloff in $IMMP due to a lack of bullish sentiment.
$IMMP's price is considered ridiculous and unrealistic given its recent FDA approval.

Generated by AI

Topics

Of the messages about IMMP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	88.46%	46.73%
Technical Analysis	100%	100%	11.54%	14.43%
Controversies	0%	0%	0%	0.51%
Analysts	0%	0%	0%	7.27%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	31.06%

Announcements· Apr 15

Immutep Limited ($IMMP) has received FDA Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma, a rare cancer with significant unmet medical need.
The designation was granted after the Phase 2 EFTISARC-NEO trial met its primary endpoint, showing a median tumor hyalinization/fibrosis rate of 51.5% in 38 patients.
The FDA Orphan Drug Designation provides 7 years of market exclusivity and is a major regulatory win for Immutep, a clinical-stage biotech focused on LAG-3 immunotherapy across cancer and autoimmune diseases.

Technical Analysis· Apr 15

Immutep Limited ($IMMP) has been forming a textbook falling wedge, which could signal a break of the downtrend.
The stock's intraday chart shows a megaphone pattern, with upside targets and a pullback zone, but the author is cautious due to decreasing volume.
$IMMP is looking good on the 4-hour chart, with key support at 0.75-0.79 and a potential next key level to test at 1.05-1.15.

Generated by AI

Community

Of the messages about IMMP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	2.68%	1.44%	11.51%	41.05%
Newcomers	97.32%	98.56%	88.49%	58.95%

Regulars· Apr 15

Immutep's eftilagimod alfa received FDA Orphan Drug Designation for soft tissue sarcoma, a major regulatory win that may put fresh eyes on the company's story.
The FDA's Orphan Drug Designation was granted after the Phase 2 EFTISARC-NEO study met its primary endpoint, showing a 51.5% median tumor hyalinization/fibrosis rate in 38 patients.
Immutep's shares have responded positively to the news, with a 132% gain in pre-market trading, and are still above the volume-weighted average price (VWAP).

Newcomers· Sep 28

Newcomers are drawn to Immutep's stock due to its explosive clinical data from the efti LAG-3 immunotherapy trial.
The stock's chart gap on high volume is seen as a promising sign for future growth.
Breakout above the resistance level of $0.36 could lead to targets of $0.43-$0.50, according to some analysts.

Generated by AI

Media Release Pooled analysis of five efti trials (presented at ASCO 2026) reinforced efti's mechanism of action, tying immune activation to a 7.7-month median overall survival benefit in biological responders across four tumour types.IMP761, the only LAG-3 agonist antibody in clinical development, delivered encouraging first-in-human results (presented at EULAR 2026), meeting its primary safety endpoint and showing significant pharmacodynamic activity.Investigation into the futility outcome fro

2mo agoYahoo Finance

Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026

SYDNEY, AUSTRALIA, July 24, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that an abstract for the investigator-initiated EFTISARC-NEO Phase II trial evaluating its first-in-class MHC Class II agonist, eftilagimod alfa (“efti”), has been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place 23–27 October

2mo agoYahoo Finance

Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor

SYDNEY, AUSTRALIA, July 14, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced the grant of a new patent (number 12,673,088) entitled “Combined Preparations for the Treatment of Cancer or Infection” by the United States Patent and Trademark Office (USPTO). This patent is the fourth in the series and follows the grant of the United States parent patent, first divisional patent, a

2mo agoYahoo Finance

Citizens maintains Immutep stock rating on cash analysis

2mo agoInvesting.com

Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004

INSIGHT-003 demonstrates mature mOS of 30.9 months in both the overall population (N=51) and patients with TPS <50% (N=47) in 1L non-squamous NSCLCOutcomes continue to compare favourably with historical benchmarksPreliminary immune monitoring data indicate that patients treated with efti in TACTI-004 exhibited a different immune activation profile compared with previous studies TACTI-004 root cause analysis is ongoing with additional results expected in Q3 CY2026 SYDNEY, AUSTRALIA, July 13, 2026

2mo agoYahoo Finance

Also Discussed

Investors talking about IMMP also mention

#	Name	Attention
1	Allied Gaming & Entertainment Inc.AGAE	0%0
2	Snail Inc. Class A Common StockSNAL	0%0
3	Onfolio Holdings, Inc.ONFO	0%-0.05
4	Greenwich LifeSciences, Inc.GLSI	0%0
5	Immuron Ltd. Sponsored ADRIMRN	0%0
6	Imperial Petroleum Inc.IMPP	0%0
7	BT Brands, Inc.BTBD	0%0
8	Baiya International Group Inc. Class A Ordinary SharesBIYA	0%new
9	Zai Lab Limited ADRZLAB	0%0
10	Xiao-I Corporation American Depositary SharesAIXI	0.01%+0.01

Immutep Ltd. ADR

Healthcare
Biotechnology

Immutep Ltd. ADR is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. The company’s programs are built around LAG-3, an immune-regulating pathway used to modulate how the body’s immune system responds to disease. Its current pipeline includes product candidates such as eftilagimod alfa, IMP761, leramilimab, and GSK’781, which are being studied across multiple therapeutic areas. Immutep Ltd. ADR operates in the biotechnology segment of the healthcare market, where it contributes to the development of next-generation biologic treatments designed to address unmet medical needs. The company is headquartered in Sydney, Australia, and its work is centered on advancing specialized immunology-based therapies for use in oncology and autoimmune care.

Website

Location

Australia Square

Sydney, NSW, 2000

Australia

Social

What share of all stock conversation is about IMMP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% -0.02	0% +0	0% +0	0% 0

Sep 28

Immutep's efti LAG-3 immunotherapy trial delivers explosive clinical data, with the company's stock experiencing a significant surge in value.
The stock's price has created a chart gap, with volume reaching monster levels.
Technical analysts see potential for the stock to break above resistance at $0.43-$0.50.

Generated by AI

Sentiment

Of the messages about IMMP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% -100	78.57% +11.9	82.54% -0.18
Bearish	—	100% new	21.43% -11.9	17.46% +0.18

Bullish· Apr 16

Immutep Limited's ($IMMP) FDA Orphan Drug Designation for efti has driven a significant price increase, with the stock potentially running toward $1.20.
The company's Phase II data and FDA momentum have caused a "burn notice" for short sellers, with the stock's volume supporting a potential run toward $1.20.
$IMMP has the potential to reach $1 or higher, with some traders predicting a 50-70% increase in value following the FDA news.

Bearish· Apr 16

$IMMP is likely to break below $1.00 and revisit $0.50.
Traders are expecting a selloff in $IMMP due to a lack of bullish sentiment.
$IMMP's price is considered ridiculous and unrealistic given its recent FDA approval.

Generated by AI

Topics

Of the messages about IMMP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	88.46%	46.73%
Technical Analysis	100%	100%	11.54%	14.43%
Controversies	0%	0%	0%	0.51%
Analysts	0%	0%	0%	7.27%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	31.06%

Announcements· Apr 15

Immutep Limited ($IMMP) has received FDA Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma, a rare cancer with significant unmet medical need.
The designation was granted after the Phase 2 EFTISARC-NEO trial met its primary endpoint, showing a median tumor hyalinization/fibrosis rate of 51.5% in 38 patients.
The FDA Orphan Drug Designation provides 7 years of market exclusivity and is a major regulatory win for Immutep, a clinical-stage biotech focused on LAG-3 immunotherapy across cancer and autoimmune diseases.

Technical Analysis· Apr 15

Immutep Limited ($IMMP) has been forming a textbook falling wedge, which could signal a break of the downtrend.
The stock's intraday chart shows a megaphone pattern, with upside targets and a pullback zone, but the author is cautious due to decreasing volume.
$IMMP is looking good on the 4-hour chart, with key support at 0.75-0.79 and a potential next key level to test at 1.05-1.15.

Generated by AI

Community

Of the messages about IMMP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	2.68%	1.44%	11.51%	41.05%
Newcomers	97.32%	98.56%	88.49%	58.95%

Regulars· Apr 15

Immutep's eftilagimod alfa received FDA Orphan Drug Designation for soft tissue sarcoma, a major regulatory win that may put fresh eyes on the company's story.
The FDA's Orphan Drug Designation was granted after the Phase 2 EFTISARC-NEO study met its primary endpoint, showing a 51.5% median tumor hyalinization/fibrosis rate in 38 patients.
Immutep's shares have responded positively to the news, with a 132% gain in pre-market trading, and are still above the volume-weighted average price (VWAP).

Newcomers· Sep 28

Newcomers are drawn to Immutep's stock due to its explosive clinical data from the efti LAG-3 immunotherapy trial.
The stock's chart gap on high volume is seen as a promising sign for future growth.
Breakout above the resistance level of $0.36 could lead to targets of $0.43-$0.50, according to some analysts.

Generated by AI

Immutep

Social

Sep 28

Bullish· Apr 16

Bearish· Apr 16

Announcements· Apr 15

Technical Analysis· Apr 15

Regulars· Apr 15

Newcomers· Sep 28

Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)

Immutep Quarterly Activities Report Q4 FY26

Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026

Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor

Citizens maintains Immutep stock rating on cash analysis

Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004

Also Discussed

Immutep Ltd. ADR

Company Information

Location

Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)

Immutep Quarterly Activities Report Q4 FY26

Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026

Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor

Citizens maintains Immutep stock rating on cash analysis

Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004

Also Discussed

Social

Sep 28

Bullish· Apr 16

Bearish· Apr 16

Announcements· Apr 15

Technical Analysis· Apr 15

Regulars· Apr 15

Newcomers· Sep 28